Skip to content
SABCS 2024 logo

SABCS 2024

3 interviews37 min

San Antonio Breast Cancer Symposium

Interviews and expert commentary from SABCS 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.

Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer

Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer

SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-base

28 March 2025
8 min
E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of can

16 January 2025
14 min
AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer

AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer

SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr

11 January 2025
15 min